Acorai’s CEO – Filip Peters grabs the pen looking back at a hectic 2025, and into the crystal ball for 2026.
In 2025,
We successfully completed and presented results from our landmark 1600-patient CAPTURE-HF study, validating Acorai’s non-invasive technology vs. the right heart catheterization gold standard.
In parallel, we delivered our next-generation device, delivering performance improvements of over 40%, expanded our intellectual property with two new patent families, and detailed our regulatory pathway through the FDA Breakthrough Device and TAP Pilot program.
We’ve continued to gain global traction throughout the year, establishing new clinical partnerships and investments in Singapore and Taiwan (driven by a $1M paid pilot with SingHealth and National Healthcare Group (NHG), and receiving recognition from cardiology societies.
Dr. Andrew Sauer presenting Acorai’s CAPTURE-HF study data during the late-breaking science session at Heart Failure Society of America conference in Minneapolis, in September
We published our whitepaper ‘The emerging role of non-invasive cardiac and pulmonary pressure sensing in inpatient cardiology and hospitalized heart failure workflow’ which was well received by the clinical community.
Our achievements resulted in multiple awards, including winning the ESC Advanced Product Technology & Innovation Award and coming in 2nd at the Medica Healthcare Innovation World Cup 2025.
This year’s achievements would not have been possible without the support of our partners and collaborators. We extend our gratitude to our:
- Clinical Partners: Including but not limited to Saint Luke’s Health System, Duke Health, MUSC Health, Rigshospitalet Copenhagen, Skåne University Hospital, Royal Brompton & Harefield, SingHealth, NHG Health and many more, for enabling ongoing and planned studies, and supporting publication of our CAPTURE-HF study data.
- Investors: We thank both our existing and new investors, including the EIC Fund, EIT Health, Cedars Sinai, Carma Fund, Golden Angel Investors, CerraCap, Flying Point Industries and several of our private investors, for their continued support in our mission.
Thank you for being part of Acorai’s journey.
In 2026,
We look forward to a pivotal year for the company, demonstrating the potential for Acorai to positively impact heart failure patient management and getting us one step closer to market approval.
As we move into 2026, we kick off Acorai’s 1,000-patient HOSP-HF pivotal study aiming to demonstrate the health economic benefits of Acorai’s solution, laying the foundation for regulatory approvals and commercialization in 2027 across US, EU and Asia.
Overview of Acorai’s 1000-patient HOSP-HF study
Acorai’s solution has transformational potential to improve heart failure patient management, which can substantially reduce admissions, readmissions, and the overall cost of care.
I am deeply grateful to our team and partners for their continued support and belief in our mission of bringing scalable & personalized heart failure solutions to patients worldwide.
As a final note,
We are always eager to engage with and deepen our relationships with the community. If you’re interested in an advisory role, clinical partnership or would like to learn more about our ongoing fundraise, we’d love to hear from you.
You can reach out directly to me at filip.peters@acorai.com
Happy holidays and all the best for 2026!
About Acorai
Acorai is dedicated to advancing non-invasive heart failure care by equipping clinicians with next-generation tools to improve patient outcomes. The company’s patented SAVE Sensor System is a pioneering multi-sensor platform designed to non-invasively estimate cardiac filling pressures, enabling more confident decision-making across the care continuum. Acorai has received FDA Breakthrough Device Designation and has studied its platform in over 2,000 patients. Supported by leading medtech investors and strategic partners, Acorai is committed to shaping the future of cardiac care through innovation in non-invasive monitoring.
For the latest updates, follow Acorai on LinkedIn or visit acorai.com
Media Contact